NCT04833582 - A Study of ZN-c3 in Combination With Gemcitabine in Subjects With Osteosarcoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 1, 2021

Primary Completion Date

August 30, 2023

Study Completion Date

December 30, 2023

Conditions

Osteosarcoma

Interventions

DRUG

ZN-c3

ZN-c3 is an investigational drug.

DRUG

Gemcitabine

Gemcitabine is an approved drug

Trial Locations (17)

10065

Site 0105, New York

13385

Site 3602, Marseille

23298

Site 0188, Richmond

31100

Site 3605, Toulouse

32610

University of Florida College of Medicine, Gainesville

33000

Site 3604, Bordeaux

37332

Site 0197, Nashville

38105

Site 0193, Memphis

45229

Site 0107, Cincinnati

69008

Site 3601, Lyon

75248

Site 3606, Paris

77030

Site 0103, Houston

90095

Site 0106, Los Angeles

90403

Site 0195, Santa Monica

94609

Site 0124, Oakland

97239

Site 0123, Portland

98195

Site 0122, Seattle

All Listed Sponsors

lead

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

INDUSTRY